Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and Molecular Dynamics Simulation
نویسندگان
چکیده
BRD4 (bromodomain-containing protein 4) is an epigenetic reader that realizes histone proteins and promotes the transcription of genes linked to cancer progression non-cancer diseases such as acute heart failure severe inflammation. The highly conserved N-terminal bromodomain (BD1) recognizes acylated lysine residues organize expression genes. As such, BD1 essential for disrupting interactions a promising target treatment. To identify new inhibitors, SuperDRUG2 database contains more than 4600 pharmaceutical compounds was screened using in silico techniques. efficiency AutoDock Vina1.1.2 software anticipate inhibitor-BRD4-BD1 binding poses first evaluated based on co-crystallized R6S ligand complex with BRD4-BD1. From screening, most BRD4-BD1 inhibitors were subsequently submitted molecular dynamics (MD) simulations integrated MM-GBSA approach. computations indicated benzonaphthyridine derivative, pyronaridine (SD003509), energy prediction (ΔGbinding) −42.7 kcal/mol comparison −41.5 positive control inhibitor (R6S). Pharmacokinetic properties predicted oral bioavailability both ligands, while post-dynamic analyses pocket demonstrated greater stability pyronaridine. These results confirm studies can provide insight into novel protein–ligand regulators, specifically potential drug candidate.
منابع مشابه
Drug Discovery Targeting Bromodomain-Containing Protein 4
BRD4, the most extensively studied member of the BET family, is an epigenetic regulator that localizes to DNA via binding to acetylated histones and controls the expression of therapeutically important gene regulatory networks through the recruitment of transcription factors to form mediator complexes, phosphorylating RNA polymerase II, and by its intrinsic histone acetyltransferase activity. D...
متن کاملBromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors
The bromodomain and extraterminal (BET) family proteins associate with transcriptional activation through interaction with acetylated chromatin, therefore playing a key role as epigenetic regulators. BET proteins serve to regulate the expression of importance oncogenes, including those involved in apoptosis as well as cell cycle progression. Due to this potential as an epigenetic target, small ...
متن کاملAcetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
Members of the bromodomain and extra terminal (BET) family of proteins are essential for the recognition of acetylated lysine (KAc) residues in histones and have emerged as promising drug targets in cancer, inflammation, and contraception research. In co-crystallization screening campaigns using the first bromodomain of BRD4 (BRD4-1) against kinase inhibitor libraries, we identified and charact...
متن کاملGrowth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4.
In a gene trap screen we recovered a mouse mutant line in which an insertion generated a null allele of the Brd4 gene. Brd4 belongs to the Fsh/Brd family, a group of structurally related proteins characterized by the association of two bromodomains and one extraterminal domain. Members of this family include Brd2/Ring3/Fsrg1 in mammals, fs(1)h in Drosophila, and Bdf1 in Saccharomyces cerevisiae...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecules
سال: 2023
ISSN: ['1420-3049']
DOI: https://doi.org/10.3390/molecules28155713